Suven Life Sciences
SUVENNSE

Suven Life Sciences

₹133.874.73 (3.66%)1D
1D
1W
1M
3M
6M
1Y
3Y
5Y
All
Create Stock SIPAutomate your investments in this
Overview
Technicals
News
Events

Performance

Today’s low
131.51
Today’s high
138.00
52 week low
113.00
52 week high
299.99
Open price
131.74
Previous close
129.14
Live volume
5,21,912
Lower circuit
107.10
Upper circuit
160.64

Fundamentals

Market Cap
₹3,527Cr
ROE
-75.33%
P/E Ratio(TTM)
-12.84
EPS(TTM)
-10.42
P/B Ratio
4.60
Dividend Yield
0.00%
Industry P/E
53.36
Book Value
29.08
Debt to Equity
0.00
Face Value
1

Financials

*All values are in Rs. Cr
No Graph Data To Display
Quarterly
Yearly

About

Suven Life Sciences is a biopharmaceutical company dedicated to discovering and developing novel pharmaceutical products for a wide range of Central Nervous System (CNS) disorders. The company's vision is to achieve a breakthrough innovation by singularly focusing on New Chemical Entities for CNS conditions, a commitment it has held for 20 years. It is uniquely positioned as the only Indian NCE-focused player with such a large basket of molecules specifically targeting disorders of the brain and spinal cord. Its core mission involves developing solutions for diseases with significant unmet medical needs, such as Alzheimer's, dementia, and narcolepsy, through its specialized research programs and clinical trials. Strategically, the company focuses on targets with novel and differentiated mechanisms of action, targeting indications that have high unmet needs and attractive commercial opportunities to ensure efficient development. This focused pursuit has resulted in a portfolio of 13 new chemical entities, which includes 7 assets in clinical stages and 6 projects in the research pipeline.;
MD/CEO
Shri Venkateswarlu Jasti
Founded in
1989
NSE symbol
SUVEN
Industry

Shareholding Pattern

Jun '25
Jul '25
Sep '25
Dec '25
Mar '26
Promoters
70.15%
Retail And Others
24.41%
Other Domestic Institutions
2.83%
Mutual Funds
1.79%
Foreign Institutions
0.81%

Mutual Funds Invested (1)

Similar stocks

StockMkt price (1D)52 week performanceMarket capP/E ratioP/B ratio
Innova CaptabINNOVACAP
₹711.55
+20.55 (2.97%)
L
    H
    4,080.1430.814
    ₹404.55
    +9.40 (2.38%)
    L
      H
      3,779.3342.175.18
      Aarti DrugsAARTIDRUGS
      ₹341.10
      +5.65 (1.68%)
      L
        H
        3,110.0315.362.12
        ₹268.15
        +3.80 (1.44%)
        L
          H
          2,927.3561.211.07
          Livesquawk
          Suven Life Sciences converts warrants to issue 3.18 Cr equity shares at ₹134 each. Total funds raised by Suven Life Sciences amount to ₹425.7 Cr.
          Livesquawk
          Suven Life Sciences reported Q3 consolidated net loss of ₹1.02B, up from ₹391.2M YoY.
          Livesquawk
          Suven Life Sciences achieves early full enrollment for Phase 2B trial of Ropanicant for MDD. Topline results from the trial are anticipated by May 2026.
          Livesquawk
          Suven Life Sciences reports Q2 net loss of ₹773M, up from ₹496M YoY.
          2026
          29
          Jan
          Quarterly Result
          Release date
          2025
          11
          Nov
          Quarterly Result
          Release date
          13
          Aug
          Quarterly Result
          Release date
          Events calendar
          View upcoming events in other stocks